Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241613 · ClinicalTrials.gov registry record · Phase 1
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Accutar Biotechnology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05241613: Clinical Trial Phase 1 study, sponsored by Accutar Biotechnology.
NCT05241613 is a Phase 1 study that was terminated before completion, run by Accutar Biotechnology. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05241613, a Phase 1 study, was terminated before completion, sponsored by Accutar Biotechnology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to participants * Evaluate the side effects of AC176 * Evaluate pharmacokinetics of AC176 * Evaluate the effectiveness of AC176
Primary Outcome
Number of subjects with DLT
Interventions
- DRUG AC176
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2024-03-05 |
| Phase | Phase 1 |
Why NCT05241613 stopped before completion
NCT05241613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which AC176 is the first listed.
NCT05241613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05241613 about?
NCT05241613 is a clinical study titled "A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer". This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to...
What is the current status of trial NCT05241613?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-03-16. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT05241613?
The interventions under investigation include: AC176 (DRUG).
Who is sponsoring clinical trial NCT05241613?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05241613's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI